DB
Dayanand Baburao Walse
About Dayanand Baburao Walse
Data last updated:
Dayanand Baburao Walse is a Partner at Epi Pharmaceuticals Llp (since 2020). The companies operate in Chemicals. Earlier, Dayanand Baburao Walse was a Director at Glucon Life Science Private Limited (from 2011).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Epi Pharmaceuticals Llp AAS-6786 | Partner | 21 Jun 2020 | 2020 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Glucon Life Science Private Limited U51909MH2011PTC221182 | Director | 23 Aug 2011 | 2011 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Dayanand Baburao Walse
| Name | DIN | Company | Designation |
|---|---|---|---|
| Pradeep Ankushrao Rachure | 08768933 | Epi Pharmaceuticals Llp | Designated Partner |
| Sanjay Mahadev Chikte | 08768934 | Epi Pharmaceuticals Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Dayanand Baburao Walse
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dayanand Baburao Walse
Dayanand Baburao Walse currently holds 1 directorship: Epi Pharmaceuticals Llp (Partner, since 21 Jun 2020).
Dayanand Baburao Walse was first appointed on 23 Aug 2011 as Director at Glucon Life Science Private Limited. The most recent appointment on record is 21 Jun 2020 at Epi Pharmaceuticals Llp.
Dayanand Baburao Walse held 1 earlier board appointment: Glucon Life Science Private Limited (Director, from 23 Aug 2011).
The current boards of Dayanand Baburao Walse's companies include Pradeep Ankushrao Rachure (Epi Pharmaceuticals Llp), Sanjay Mahadev Chikte (Epi Pharmaceuticals Llp).